4NX1.F · Lumos Pharma, Inc

-

Please sign in to comment on 4NX1.F

1 Comment

Admin

3 years, 8 months ago

Lumos Pharma, Inc is currently in a long term downtrend where the price is trading 32.7% below its 200 day moving average.

From a valuation standpoint, the stock is 64.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 466.0.

Lumos Pharma, Inc's total revenue sank by 90.8% to $40K since the same quarter in the previous year.

Its net income has increased by 70.8% to $-2M since the same quarter in the previous year.

Finally, its free cash flow grew by 12.9% to $-7M since the same quarter in the previous year.

Based on the above factors, Lumos Pharma, Inc gets an overall score of 3/5.

ISIN	None
CurrencyCode	EUR
Industry
Sector
Exchange	F

Beta	nan
Market Cap	64M
Target Price	27
PE Ratio	None
Dividend Yield	None

ABOUT

Lumos Pharma, Inc

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas.

4NX1.F · Lumos Pharma, Inc

-

Lumos Pharma, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Lumos Pharma, Inc using a moving average strategy